Search Results

[NUVISAN Talk] How to Translate Your Oncology Target into a Preclinical Candidate - Part 2

[NUVISAN Talk] How to Translate Your Oncology Target into a Preclinical Candidate - Part 2

[NUVISAN Talk] How to Optimize your Clinical Drug Supply: Tailored Solutions for Clinical Success

[NUVISAN Talk] How to Optimize your Clinical Drug Supply: Tailored Solutions for Clinical Success

[NUVISAN Talk] How to Augment the Value of Your Regulatory CYP Induction Study

[NUVISAN Talk] How to Augment the Value of Your Regulatory CYP Induction Study

TRANSLATING FROM TARGET TO CLINICAL TRIAL: WHAT YOU NEED TO KNOW ABOUT PRECLINICAL STUDIES

TRANSLATING FROM TARGET TO CLINICAL TRIAL: WHAT YOU NEED TO KNOW ABOUT PRECLINICAL STUDIES

How to Evaluate Preclinical and Clinical DILI

How to Evaluate Preclinical and Clinical DILI

Cancer Discovery and Preclinical Validation Using Patient-Derived Xenografts

Cancer Discovery and Preclinical Validation Using Patient-Derived Xenografts

Lost in translation: learning from preclinical data | Gerry Davies

Lost in translation: learning from preclinical data | Gerry Davies

[Webinar] The Strategies of NK Cell Related IO Therapy in Preclinical Drug Evaluation (20220726 2nd)

[Webinar] The Strategies of NK Cell Related IO Therapy in Preclinical Drug Evaluation (20220726 2nd)

The advantages of patient-derived using xenograft models for preclinical oncology research

The advantages of patient-derived using xenograft models for preclinical oncology research

Bench to Bedside: Designing pre-clinical studies to support in-human trials. (Part 1 of 2)

Bench to Bedside: Designing pre-clinical studies to support in-human trials. (Part 1 of 2)

ESCMID/ASM Conference 2022 Bootcamp 2 : Discovery and preclinical development challenges

ESCMID/ASM Conference 2022 Bootcamp 2 : Discovery and preclinical development challenges

The Bench to Bedside Series: Preclinical Cancer Research with Scintica

The Bench to Bedside Series: Preclinical Cancer Research with Scintica